Patent Issued for Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-a (USPTO 11897951).
In: Immunotherapy Weekly, 2024-03-08, S. 2515-2515
serialPeriodical
Zugriff:
Ablynx N.V. has been granted a patent for polypeptides that target IL-6 and TNF-a, which are involved in rheumatoid arthritis and other inflammatory diseases. The patent discusses the use of bispecific antibodies to target multiple disease factors, eliminating the need for separate treatments. The development of more effective therapies for rheumatoid arthritis is still needed, and this patent explores the potential of targeting both IL-6 and TNF-a with a single agent. The polypeptides developed have shown increased efficiency in modulating symptoms compared to current therapies and can be easily produced and administered. The patent also includes claims related to the composition, production, and use of these polypeptides for treating inflammatory and autoimmune diseases, specifically rheumatoid arthritis. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-a (USPTO 11897951).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-03-08, S. 2515-2515 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|